Investigational drug · Phase 2
HSK47388
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis, Ulcerative Colitis (UC).
Phase 2Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HSK47388"
First trial start
2025
Sep 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK47388", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- Ulcerative Colitis (UC)
Approved drugs for the same conditions: Plaque psoriasis · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK47388" as an intervention, largest first.
- A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07158268 · 220 participants (planned) · Start Sep 1, 2025 · Primary completion Dec 20, 2026
Drug: HSK47388 · For: Plaque Psoriasis
- A Study for HSK47388 in Participants With Ulcerative ColitisPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07335055 · 150 participants (planned) · Start Feb 3, 2026 · Primary completion Oct 15, 2027
Drug: HSK47388; Placebo · For: Ulcerative Colitis (UC)
Sites: Hangzhou, China
- This Study is to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of HSK47388 in Healthy VolunteersNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06926218 · 40 participants (planned) · Start May 2025 · Primary completion Jul 2025
Drug: HSK47388; Placebo · For: Healthy
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.